Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1G9WkBh
from Today's Healthcare News -- ScienceDaily http://ift.tt/1G9WkBh
No comments:
Post a Comment